William Blair research analyst Matt Phipps was quoted in MedCity News following Bristol Myers Squibb’s acquisition of Mirati Therapeutics. Phipps weighed in on the target of the acquisition, cancer drug Krazati.
Equity Research
Matt Phipps Highlights Impact of Acquisition by Bristol Myers Squibb in MedCity News
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
-
Monthly Macro: Fed Signals, Housing Headwinds, and How Companies Are Adapting
William Blair macro analyst Richard de Chazal discusses the Fed’s softer tone, how companies are adapting to tariffs and labor shifts, and why housing and hiring trends are setting the stage for a dynamic second half of 2025.
-